Outputs (6)

Nanotechnologies in Pancreatic Cancer Therapy. (2017)
Journal Article
Manzur, A., Hoskins, C., Oluwasanmi, A., Moss, D., & Curtis, A. (2017). Nanotechnologies in Pancreatic Cancer Therapy. Pharmaceutics, https://doi.org/10.3390/pharmaceutics9040039

Pancreatic cancer has been classified as a cancer of unmet need. After diagnosis the patient prognosis is dismal with few surviving over 5 years. Treatment regimes are highly patient variable and often the patients are too sick to undergo surgical re... Read More about Nanotechnologies in Pancreatic Cancer Therapy..

Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy (2017)
Journal Article
Oluwasanmi, A., Al-Shakarchi, W., Manzur, A., Aldebasi, M. H., Elsini, R. S., Albusair, M. K., …Hoskins, C. (2017). Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy. Journal of Controlled Release, 355-364. https://doi.org/10.1016/j.jconrel.2017.09.027

Hybrid nanoparticles (HNPs) have shown huge potential as drug delivery vehicles for pancreatic cancer. Currently, the first line treatment, gemcitabine, is only effective in 23.8% of patients. To improve this, a thermally activated system was develop... Read More about Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.

Thermally Triggered Theranostics for Pancreatic Cancer Therapy (2017)
Journal Article
Malekigorji, M., Alfahad, M., Kong Thoo Lin, P., Jones, S., Curtis, A., & Hoskins, C. (2017). Thermally Triggered Theranostics for Pancreatic Cancer Therapy. Nanoscale, https://doi.org/10.1039/C7NR02751F

Hybrid iron oxide-gold nanoparticles (HNPs) are capable of drug binding onto their surface with a triggered release at elevated temperatures. The iron oxide core allows for diagnostic imaging whilst heating of the gold shell upon laser irradiation re... Read More about Thermally Triggered Theranostics for Pancreatic Cancer Therapy.

The co-administration of anticancer and pro-apoptotic agents as novel approach in liver cancer therapy (2017)
Presentation / Conference
Varbiro, G., Curtis, A., Hoskins, C., & Al Shakarchi, W. (2017, April). The co-administration of anticancer and pro-apoptotic agents as novel approach in liver cancer therapy. Presented at European Nanomedicine Meeting, London

Further correction: Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy (2017)
Journal Article
Khare, V., Sakarchi, W., Gupta, P., Curtis, A., & Hoskins, C. (2017). Further correction: Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy. RSC advances, 17367 - 17367. https://doi.org/10.1039/C7RA90041D

Further correction for ’Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy’ by Vaibhav Khare et al., RSC Adv., 2016, 6, 60126-60137.

Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy (2017)
Journal Article
Khare, V., Al Sakarchi, W., Gupta, P., Curtis, A., & Hoskins, C. (2017). Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy. RSC advances, 12598 - 12598. https://doi.org/10.1039/C7RA90021J

Correction for ‘Synthesis and characterization of TPGS–gemcitabine prodrug micelles for pancreatic cancer therapy’ by Vaibhav Khare et al., RSC Adv., 2016, 6, 60126–60137.